EXECUTIVE INTERVIEW – Novozymes Biopharma: Improving Drug Safety & Stability With Recombinant Human Albumin
Mark Perkins, Customer Solution Manager at Novozymes Biopharma, discusses how the company is improving the formulation of many new drugs and offering customers new ways of achieving a competitive advantage.
DRUG DELIVERY – Recent Advancements in Drug Delivery: Novel Formulations & Technologies Offer Improved Treatment Options
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, highlights a few recent innovative approaches to drug delivery with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
Gerallt Williams, PhD, takes a look at the market forces driving DPI innovation and focuses on a novel solution that has simplicity at the heart of its design, and which hopes to address the growing pressure to reduce healthcare costs, as well as the needs of new markets, arising from emerging economies in South America, India, and China.
Frost & Sullivan Analysts Winny Tan, PhD, and Jennifer Brice highlight two dynamic pharmaceutical service segments, CROs and IVD manufacturers, and how they are evolving to meet the growing preclinical and clinical trial needs of pharmaceutical companies. They also discuss open innovation models for outsourcing the earliest stage of drug discovery.
Dinesh Haswani, PhD; John Nagel, MBA; Derek Moe, PhD; and Ehab Hamed, PhD; say formulations developed using OraGuard technology provide overlapping resistance against various tampering methods, such as crushing and ingestion, chewing, small-volume extract
BIOAVAILABILITY ENHANCEMENT – Overcoming Poorly Soluble Pharmaceutical Formulations With Hot Melt Extrusion
INTRODUCTION Solubility is an essential characteristic of active pharmaceutical ingredients (APIs), with profound effects on process and clinical development, formulation, and commercialization. Higher-solubility drugs dissolve…
FORMULATION DEVELOPMENT – Recombinant Human Albumin: Delivering the Future of Type 2 Diabetes Medication
Mark Perkins, PhD, discusses the application of human serum albumin as a half-life extension technology for GLP-1 therapeutics and how further developments in recombinant human albumin technology may further change the dosing paradigm.
David M. Kleinman, MD; Andrew Loxley, PhD; Gillian M. Tocci, PhD; George Ngwa, PhD; William Gensheimer, MD; and Robert W. Lee, PhD; indicate PEGPLUS, a multifunctional graft copolymer, can be used in a host of topical ophthalmic applications.
EXCIPIENT UPDATE – Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions
Rod Ray, PhD, explains that because more than half of the compounds in early development are considered poorly soluble, improving oral bioavailability represents a significant challenge to the pharmaceutical industry.
N.V. Satheesh Madhav, PhD, MPharm; and Pranshu Tangri, MPharm; formulate and evaluate sustained-release tablets of atorvastatin using a biomaterial isolated from unripe fruit pulp as a novel biobinder for the formulation of tablets.
EXCLUSIVE ONLINE CONTENT
Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone
Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
uniQure N.V. recently announced it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.